These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12757727)

  • 81. Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold.
    Ohkanda J; Lockman JW; Kothare MA; Qian Y; Blaskovich MA; Sebti SM; Hamilton AD
    J Med Chem; 2002 Jan; 45(1):177-88. PubMed ID: 11754590
    [TBL] [Abstract][Full Text] [Related]  

  • 82. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
    J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract]   [Full Text] [Related]  

  • 83. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF.
    Girgert R; Wittrock J; Pfister S; Schweizer P
    J Cancer Res Clin Oncol; 2003 Apr; 129(4):227-33. PubMed ID: 12700894
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase.
    Wang GT; Wang X; Wang W; Hasvold LA; Sullivan G; Hutchins CW; O'Conner S; Gentiles R; Sowin T; Cohen J; Gu WZ; Zhang H; Rosenberg SH; Sham HL
    Bioorg Med Chem Lett; 2005 Jan; 15(1):153-8. PubMed ID: 15582430
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway.
    Reuveni H; Geiger T; Geiger B; Levitzki A
    J Cell Biol; 2000 Dec; 151(6):1179-92. PubMed ID: 11121434
    [TBL] [Abstract][Full Text] [Related]  

  • 86. C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.
    McNamara DJ; Dobrusin E; Leonard DM; Shuler KR; Kaltenbronn JS; Quin J; Bur S; Thomas CE; Doherty AM; Scholten JD; Zimmerman KK; Gibbs BS; Gowan RC; Latash MP; Leopold WR; Przybranowski SA; Sebolt-Leopold JS
    J Med Chem; 1997 Oct; 40(21):3319-22. PubMed ID: 9341905
    [No Abstract]   [Full Text] [Related]  

  • 87. Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity.
    Kettler K; Wiesner J; Silber K; Haebel P; Ortmann R; Sattler I; Dahse HM; Jomaa H; Klebe G; Schlitzer M
    Eur J Med Chem; 2005 Jan; 40(1):93-101. PubMed ID: 15642414
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pepticinnamins, new farnesyl-protein transferase inhibitors produced by an actinomycete. II. Structural elucidation of pepticinnamin E.
    Shiomi K; Yang H; Inokoshi J; Van der Pyl D; Nakagawa A; Takeshima H; Omura S
    J Antibiot (Tokyo); 1993 Feb; 46(2):229-34. PubMed ID: 8468236
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
    Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V
    Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
    J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
    [TBL] [Abstract][Full Text] [Related]  

  • 91. From peptide libraries to optimized nonpeptide ligands in the search for S-farnesyltransferase inhibitors.
    Henlin JM; Boutin JA; Kucharczyk N; Desmet-Beaufort C; Loynel A; Bertrand M; Genton A; Tucker GC; Atassi G; Fauchére JL
    J Pept Res; 2001 Feb; 57(2):85-96. PubMed ID: 11168892
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Inhibitors of Ras farnesyltransferases.
    Tamanoi F
    Trends Biochem Sci; 1993 Sep; 18(9):349-53. PubMed ID: 8236454
    [TBL] [Abstract][Full Text] [Related]  

  • 93. RhoB and the cellular response to farnesyltransferase inhibitors: the search for clues to cell death mechanisms.
    Bernhard EJ
    Cancer Biol Ther; 2003; 2(3):281-2. PubMed ID: 12878866
    [No Abstract]   [Full Text] [Related]  

  • 94. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of aralkylsubstituted benzophenones.
    Mitsch A; Wissner P; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2001 Feb; 334(2):40-4. PubMed ID: 11268773
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Hydrophobicity and functionality maps of farnesyltransferase.
    Ahmed S; Majeux N; Caflisch A
    J Mol Graph Model; 2001; 19(3-4):307-17, 380-7. PubMed ID: 11449569
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Farnesyltransferase inhibition: a novel method of immunomodulation.
    Si MS; Ji P; Tromberg BJ; Lee M; Kwok J; Ng SC; Imagawa DK
    Int Immunopharmacol; 2003 Apr; 3(4):475-83. PubMed ID: 12689653
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Assays for inhibitors of CAAX farnesyltransferase in vitro and in intact cells.
    James GL; Brown MS; Goldstein JL
    Methods Enzymol; 1995; 255():38-46. PubMed ID: 8524124
    [No Abstract]   [Full Text] [Related]  

  • 98. Synthesis and screening of a CaaL peptide library versus FTase reveals a surprising number of substrates.
    Krzysiak AJ; Aditya AV; Hougland JL; Fierke CA; Gibbs RA
    Bioorg Med Chem Lett; 2010 Jan; 20(2):767-70. PubMed ID: 20005705
    [TBL] [Abstract][Full Text] [Related]  

  • 99. An evolutionary approach for structure-based design of natural and non-natural peptidic ligands.
    Budin N; Ahmed S; Majeux N; Caflisch A
    Comb Chem High Throughput Screen; 2001 Dec; 4(8):661-73. PubMed ID: 11812261
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Structure-Guided Discovery of Potent Antifungals that Prevent Ras Signaling by Inhibiting Protein Farnesyltransferase.
    Wang Y; Xu F; Nichols CB; Shi Y; Hellinga HW; Alspaugh JA; Distefano MD; Beese LS
    J Med Chem; 2022 Oct; 65(20):13753-13770. PubMed ID: 36218371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.